依诺肝素与阿司匹林预防全髋或全膝关节置换术后静脉血栓栓塞的成本效益:CRISTAL整群随机试验分析
基于CRISTAL试验数据的经济学分析,评估全髋或全膝关节置换术后使用依诺肝素对比阿司匹林预防症状性静脉血栓栓塞的医疗成本与收益。依诺肝素在术后90天内预防症状性静脉血栓栓塞更有效(风险差1.97%,95%CI 0.54%至3.41%;p=0.007),但每获得一个质量调整生命年的增量成本为50,567澳元(95%CI 15,513至被支配),有60%的把握认为增量成本效果比不超过70,000澳元/质量调整生命年的支付意愿阈值。结论为依诺肝素减少静脉血栓栓塞的证据强,但相对于阿司匹林的净经济学获益证据弱。
要点
- 依诺肝素较阿司匹林降低全髋或全膝关节置换术后90天内症状性静脉血栓栓塞风险差1.97%(95%CI 0.54%至3.41%;p=0.007)。
- 依诺肝素每获得一个质量调整生命年的增量成本为50,567澳元(95%CI 15,513至被支配),有60%把握不超过70,000澳元/质量调整生命年阈值。
- 将静脉血栓栓塞治疗成本提高并延长至两年,分别有70%和63%的把握认为依诺肝素具有良好成本效益。
核心结论
- 该分析提供强证据表明全髋或全膝关节置换术后依诺肝素血栓预防减少了静脉血栓栓塞,但相对于阿司匹林的净经济学获益证据弱。
- 如果避免静脉血栓栓塞的价值高且静脉血栓栓塞相关健康损害的可能性大,则可更有信心认为依诺肝素相对于阿司匹林具有成本效益。
研究设计与样本
- 基于CRISTAL整群随机试验数据的试验经济学分析,以2022年澳元报告每获得一个质量调整生命年的增量成本,并与70,000澳元/质量调整生命年的单一阈值比较。
- 事件成本基于静脉血栓栓塞和出血的发生及已发表的治疗指南估算,单位成本取自澳大利亚来源,质量调整生命年使用CRISTAL六个月随访数据估算。
- 敏感性分析包括改变静脉血栓栓塞治疗成本以及将分析延长至两年。
主要发现
- CRISTAL试验发现依诺肝素在预防全髋或全膝关节置换术后90天内症状性静脉血栓栓塞方面比阿司匹林更有效(风险差1.97%(95%CI 0.54%至3.41%;p=0.007))。
- 全髋或全膝关节置换术后依诺肝素的额外成本为83澳元(95%CI 68至97),依诺肝素额外获得0.002个质量调整生命年(95%CI -0.002至0.005)。
- 依诺肝素每获得一个质量调整生命年的增量成本为50,567澳元(95%CI 15,513至被支配)。
- 有60%的把握认为每质量调整生命年的增量成本不超过70,000澳元的支付意愿阈值。
- 提高静脉血栓栓塞治疗成本并将成本和结局延长至两年,分别提示有70%和63%的把握认为依诺肝素具有良好成本效益。
关键数值与推荐
- 依诺肝素对比阿司匹林预防全髋或全膝关节置换术后90天内症状性静脉血栓栓塞的风险差为1.97%(95%CI 0.54%至3.41%;p=0.007)。
- 依诺肝素的额外成本为83澳元(95%CI 68至97),额外获得0.002个质量调整生命年(95%CI -0.002至0.005)。
- 每获得一个质量调整生命年的增量成本为50,567澳元(95%CI 15,513至被支配),有60%把握不超过70,000澳元/质量调整生命年阈值。
- 提高静脉血栓栓塞治疗成本后有70%把握、将分析延长至两年后有63%把握认为依诺肝素具有良好成本效益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出相对于阿司匹林的净经济学获益证据弱。
- 原文报告有60%的把握认为每质量调整生命年的增量成本不超过70,000澳元的支付意愿阈值。
- 原文报告依诺肝素额外获得0.002个质量调整生命年(95%CI -0.002至0.005),置信区间跨0。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to evaluate the healthcare costs and benefits of enoxaparin compared to aspirin in the prevention of symptomatic venous thromboembolism (VTE) after total hip arthroplasty (THA) or total knee arthroplasty (TKA) using data from the CRISTAL trial. METHODS: This trial-based economic analysis reports value for money as incremental cost per quality-adjusted life-year (QALY) gained in 2022 Australian dollars, compared to a single threshold value of AUD$70,000 per QALY. Event costs were estimated based on occurrence of VTEs and bleeds, and on published guidelines for treatment. Unit costs were taken from Australian sources. QALYs were estimated using CRISTAL six-month follow-up data. Sensitivity analyses are presented that vary the cost of VTE treatment, and extend the analyses to two years. RESULTS: The CRISTAL trial found that enoxaparin was more effective than aspirin in preventing symptomatic VTE within 90 days of THA or TKA (risk difference 1.97% (95% confidence interval (CI) 0.54% to 3.41%; p = 0.007)). The additional cost after a THA or TKA was AUD$83 (95% CI 68 to 97) for enoxaparin, and enoxaparin resulted in an additional 0.002 QALYs (95% CI -0.002 to 0.005). Incremental cost per QALY gained was AUD$50,567 (95% CI 15,513, dominated) for enoxaparin. We can be 60% confident that the incremental cost per QALY does not exceed the willingness-to-pay threshold of AUD$70,000. Increasing the cost of VTE treatment and extension of costs and consequences to two years suggested greater confidence that enoxaparin is good value for money (70% and 63% confidence, respectively). CONCLUSION: This analysis provides strong evidence that enoxaparin thromboprophylaxis following THA or TKA reduced VTEs, but weak evidence of net economic benefits over aspirin. If the value of avoiding VTEs is high, and there is a strong likelihood of VTE-related health impairments, we can be more confident that enoxaparin is cost-effective compared to aspirin.
引用
- Cost-effectiveness of enoxaparin versus aspirin in the prevention of venous thromboembolism after total hip or knee arthroplasty: an analysis from the CRISTAL cluster-randomized trial. Bone Joint J. 2024. PMID: 38821513. doi:10.1302/0301-620X.106B6.BJJ-2023-0783.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。